CR Intrinsic Investors’s Biogen BIIB Stock Holding History

CR Intrinsic Investors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-13,000	Closed	-$3.98M	–	27
2014 Q1	$3.98M	Buy	+13,000	New	+$4.13M	0.15%	191

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CR Intrinsic Investors's BIIB Position: Q2 2014 in Review

CR Intrinsic Investors sold out of Biogen (BIIB) in Q2 2014, closing a stake of 13,000 shares — an estimated $3.98M sold.

CR Intrinsic Investors first reported a position in BIIB in Q1 2014 and held it in 1 quarter. The position peaked at $3.98M in Q1 2014. 782 funds tracked by Wall St. Rank hold BIIB as of Q2 2014.

CR Intrinsic Investors reported no remaining Biogen position as of Q2 2014 after selling out during the quarter.
CR Intrinsic Investors sold 13,000 Biogen shares in Q2 2014, an estimated $3.98M.
CR Intrinsic Investors first reported a position in Biogen in Q1 2014 and held it in 1 quarter.
CR Intrinsic Investors's Biogen position peaked at $3.98M in Q1 2014.
782 funds tracked by Wall St. Rank held Biogen as of Q2 2014.

Based on CR Intrinsic Investors's 13F filing for Q2 2014.